Repeated resections for liver metastasis from primary adrenocortical carcinoma: A case report

Nakano, Ryoko; Satoh, Daisuke; Nakajima, Hirochika; Yoshimura, Yuichi; Miyoshi, Hisanobu; Yoshida, Kazuhiro; Matsukawa, Hiroyoshi; Shiozaki, Shigehiro; Ichimura, Kouichi; Okajima, Masazumi; Ninomiya, Motoki

doi:10.1016/j.ijscr.2015.02.041

Cited by 4 publications

(3 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Median OS of metastatic ACC patients varies between 10 and 20 months (2,3,5), with 5-year survival around 10% (3,6,8). However, some long-term survivors are described, including a few cases with synchronous metastases at the time of diagnosis (15,16,17,18,19,20). These observations suggest that some ACC have a slow natural history, in contrast with the usual poor prognosis of this malignancy.…”

Section: Introductionmentioning

confidence: 99%

MANAGEMENT OF ENDOCRINE DISEASE: Adrenocortical carcinoma: differentiating the good from the poor prognosis tumors

Jouinot

Bertherat

2018

European Journal of Endocrinology

View full text Add to dashboard Cite

Adrenocortical carcinoma (ACC) is a rare malignancy with a poor prognosis, the five-years overall survival being below 40%. However, there is great variability of outcomes and we have now a better view of the heterogeneity of tumor aggressiveness. The extent of the disease at the time of diagnosis, best assayed by the European Network for the Study of Adrenal Tumors (ENSAT) Staging Score, is a major determinant of survival. The tumor grade, including the mitotic count and the Ki67 proliferation index, also appears as a strong prognostic factor. The assessment of tumor grade, even by expert pathologists, still suffers from inter-observer reproducibility. The emergence of genomics in the last decade has revolutionized the knowledge of molecular biology and genetics of cancers. In ACC, genomic approaches - including pan-genomic studies of gene expression (transcriptome), recurrent mutations (exome or whole-genome sequencing), chromosome alterations, DNA methylation (methylome), miRNA expression (miRnome) - converge in a new classification of ACC, characterized by distinct molecular profiles and very different outcomes. Targeted measurements of a few discriminant molecular alterations have been developed in the perspective of clinical routine, and thus, may help defining therapeutic strategy. By individualizing patients' prognosis and tumor biology, these recent progresses appear as an important step forward towards precision medicine.

show abstract

Section: Introductionmentioning

confidence: 99%

MANAGEMENT OF ENDOCRINE DISEASE: Adrenocortical carcinoma: differentiating the good from the poor prognosis tumors

Jouinot

Bertherat

2018

European Journal of Endocrinology

View full text Add to dashboard Cite

show abstract

“… 15 Surgical resection alone is often reported to be useful for the treatment of liver metastases. 16 , 17 If complete resection is possible, a long-term prognosis can be expected. Moreover, Datrice et al 16 reported that patients with ACC with recurrence >12 months after adrenalectomy had favorable outcomes.…”

Section: Discussionmentioning

confidence: 99%

A Case of Adrenocortical Carcinoma With a Favorable Tumor Control by Radiofrequency Ablation for Liver Metastasis

Kitsugi,

Kawata,

Kakizawa

et al. 2023

Journal of Investigative Medicine High Impact Case Reports

View full text Add to dashboard Cite

A 57-year-old woman was diagnosed with adrenocortical carcinoma. Following the adrenalectomy, she underwent adjuvant radiation and mitotane therapy; however, liver metastases were observed. Repeated radiofrequency ablation (RFA) was performed for liver metastases. In addition, a multidisciplinary approach combining systemic chemotherapy, radiotherapy, and surgery was used for lung and distant lymph node metastases that arose during the course of treatment. Notably, 49 months have passed since the adrenalectomy and 36 months since the recurrence of the liver metastases, and the patient remains on multidisciplinary therapy. Thus, RFA for liver metastasis of adrenocortical carcinoma may be an effective component of a multidisciplinary treatment.

show abstract

“…Thus, the surgical approach remains the best-recommended treatment modality as long as the metastases of ACC are resectable completely (2). Some studies have suggested that surgical resection of the metastasis or recurrent for ACC is associated with prolonged survival in selected patients (5,12). However, a complete cure is unlikely to be achieved after metastasectomy.…”

Section: Discussionmentioning

confidence: 99%

A case of metastatic liver cancer with hormone secretion: a case report

2021

View full text Add to dashboard Cite

Adrenocortical carcinoma (ACC) is a rare and challenging cancer with an incidence of 0.72 per million cases per year (1) and with a poor prognosis (2). ACC affects females more frequently than males (1.5:1) (3). The patients usually suffer from primary or metastatic tumors, and 40-60% of the tumors have hormone secretion function to cause Cushing's syndrome (CS) and hypercortisolism (4).Unfortunately, metastatic and recurrent of ACC exhibit poor 5-survival rates of less than 15% (2), the optimal management and clinical outcomes of ACC remain illdefined. Due to the failure of effective treatment, surgery remains the main treatment for ACC, which includes distant resectable metastases and ACC recurrent (2).

show abstract

Repeated resections for liver metastasis from primary adrenocortical carcinoma: A case report

Cited by 4 publications

References 19 publications

MANAGEMENT OF ENDOCRINE DISEASE: Adrenocortical carcinoma: differentiating the good from the poor prognosis tumors

MANAGEMENT OF ENDOCRINE DISEASE: Adrenocortical carcinoma: differentiating the good from the poor prognosis tumors

A Case of Adrenocortical Carcinoma With a Favorable Tumor Control by Radiofrequency Ablation for Liver Metastasis

A case of metastatic liver cancer with hormone secretion: a case report

Contact Info

Product

Resources

About